title: [Characteristics of immune response to etiotropic and pathogenetic therapy in children with chronic hepatitis C].
abstract: Features of the immune response of children with chronic hepatitis C to the antiviral and pathogenetic therapy have been studied. It is shown that the antiviral therapy is accompanied by stimulation of the immune response as manifested by the synthesis of cytokines (IL-4, IFN-alpha, IFN-gamma) with retention of increased production of IFN-a for more than two years after the end of the course of treatment. In children that previously received interferon inductor (cycloferon) for 12 months, high level of IFN-a production is retained, which ensures antiviral protection. Phytotherapy did not influence the production of cytokines.
authors.forename: D K
authors.initials: DK
authors.lastname: Vasil'eva
authors.forename: L G
authors.initials: LG
authors.lastname: Goriacheva
authors.forename: N E
authors.initials: NE
authors.lastname: Monakhova
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D015847:Interleukin-4 / Q000097:blood / Q000276:immunology; D008517:Phytotherapy / Q000379:methods; D028321:Plant Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000166:Acridines; D000998:Antiviral Agents; C508598:IL4 protein, human; D007369:Interferon Inducers; D016898:Interferon-alpha; D028321:Plant Preparations; D015847:Interleukin-4; D007371:Interferon-gamma; C026430:10-carboxymethyl-9-acridanone